BiotechTube

Bococizumab (PF-04950615;RN316)

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia

Trial Timeline

Oct 23, 2013 → Apr 15, 2016

NCT ID
NCT01968980

About Bococizumab (PF-04950615;RN316)

Bococizumab (PF-04950615;RN316) is a phase 3 stage product being developed by Pfizer for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01968980. Target conditions include Heterozygous Familial Hypercholesterolemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01968980Phase 3Completed
NCT01968954Phase 3Completed

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
AZD0780 + PlaceboAstraZenecaPhase 3
77
Anacetrapib + Placebo for anacetrapibMerckPhase 3
77
Enlicitide Decanoate + PlaceboMerckPhase 2/3
65
InclisiranNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
FluvastatinNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
Evolocumab + PlaceboAmgenPhase 3
76
Atorvastatin + AtorvastatinPfizerPhase 1
32
IBI306 + placeboInnovent BiologicsPhase 3
76
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
76
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + PlaceboSanofiPhase 3
76
Placebo + AlirocumabSanofiPhase 3
76
PraluentSanofiApproved
84
AK102 + Placebo + Statins and/or EzetimibeAkesoPhase 2
51
lerodalcibepMedpacePhase 3
74
mipomersen sodium + placeboIonis PharmaceuticalsPhase 3
74
MGL-3196 (resmetirom) + PlaceboMadrigal PharmaceuticalsPhase 2
49

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84